recent pharma news

View All

covid-news
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...

Find More

pharma news
AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure

AstraZeneca aims for summer start for COVID-19 antibody trial AstraZeneca has made its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The giant is utilizing its discovery capabilities and assisting in assessing the candidates who were identified in China and the U.S...

Find More

pharma news
Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19

Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBC Immunomedics- a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan aimed at treating metastatic triple-negative brea...

Find More

COVID-19 Pharma News
J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M

Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19.  The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The ...

Find More

Pharma News
FDA permits COVID-19 treatment, Roche’s antibiotics pact, Moderna’s vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million

FDA permits COVID-19 treatments with blood from survivors The FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and that might have beneficial antibodies. It is being used as an investigational treatment for patients with severe cases of t...

Find More

Pharma-News
Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid

Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020.  The company has been acquirin...

Find More

pharma news
Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial

Sage Therapeutics seeking out to save flunked depression drug  Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allost...

Find More

Pharma News
Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib

Moderna announces dozing of first patient with its mRNA1273 vaccine The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clin...

Find More

Pharma News
JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)  The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...

Find More

Pharma News
CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment

Killing brain tumors with the help of CAR-T CAR-T cell therapy is a technique which involves modifying patients' T cells to aim proteins associated with cancer that have revolutionized some of the blood cancers treatment. However, the technique has so far shown low potential in solid tumors like aggressive brain...

Find More